BAI1 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 3
- PROTOCOLS
- BACKGROUND
Application
| FC, IHC-P, WB, E |
---|---|
Primary Accession | O14514 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 173501 Da |
Antigen Region | 1537-1567 aa |
Gene ID | 575 |
---|---|
Other Names | Brain-specific angiogenesis inhibitor 1, BAI1 |
Target/Specificity | This BAI1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1537-1567 amino acids from the C-terminal region of human BAI1. |
Dilution | WB~~1:1000 IHC-P~~1:10~50 FC~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | BAI1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | ADGRB1 (HGNC:943) |
---|---|
Function | Phosphatidylserine receptor which enhances the engulfment of apoptotic cells (PubMed:24509909). Also mediates the binding and engulfment of Gram-negative bacteria (PubMed:26838550). Stimulates production of reactive oxygen species by macrophages in response to Gram-negative bacteria, resulting in enhanced microbicidal macrophage activity (PubMed:26838550). In the gastric mucosa, required for recognition and engulfment of apoptotic gastric epithelial cells (PubMed:24509909). Promotes myoblast fusion (By similarity). Activates the Rho pathway in a G-protein-dependent manner (PubMed:23782696). Inhibits MDM2-mediated ubiquitination and degradation of DLG4/PSD95, promoting DLG4 stability and regulating synaptic plasticity (By similarity). Required for the formation of dendritic spines by ensuring the correct localization of PARD3 and TIAM1 (By similarity). Potent inhibitor of angiogenesis in brain and may play a significant role as a mediator of the p53/TP53 signal in suppression of glioblastoma (PubMed:11875720). |
Cellular Location | Cell membrane; Multi-pass membrane protein. Cell projection, phagocytic cup {ECO:0000250|UniProtKB:Q3UHD1}. Cell junction, focal adhesion {ECO:0000250|UniProtKB:Q3UHD1}. Cell projection, dendritic spine {ECO:0000250|UniProtKB:C0HL12}. Postsynaptic density {ECO:0000250|UniProtKB:Q3UHD1} [Vasculostatin-40]: Secreted |
Tissue Location | Expressed in brain (at protein level) (PubMed:12074842, PubMed:12507886). Expressed on mononuclear phagocytes and monocyte-derived macrophages in the gastric mucosa (at protein level) (PubMed:24509909). Expressed in normal pancreatic tissue but not in pancreatic tumor tissue (PubMed:11875720). Reduced or no expression is observed in some glioblastomas (PubMed:12507886) |
Provided below are standard protocols that you may find useful for product applications.
Background
Angiogenesis is controlled by a local balance between stimulators and inhibitors of new vessel growth and is suppressed under normal physiologic conditions. Angiogenesis has been shown to be essential for growth and metastasis of solid tumors. In order to obtain blood supply for their growth, tumor cells are potently angiogenic and attract new vessels as results of increased secretion of inducers and decreased production of endogenous negative regulators. BAI1 contains at least one 'functional' p53-binding site within an intron, and its expression has been shown to be induced by wildtype p53. There are two other brain-specific angiogenesis inhibitor genes, designated BAI2 and BAI3 which along with BAI1 have similar tissue specificities and structures, however only BAI1 is transcriptionally regulated by p53. BAI1 is postulated to be a member of the secretin receptor family, an inhibitor of angiogenesis and a growth suppressor of glioblastomas.
References
Kaur, B., et al., Am. J. Pathol. 162(1):19-27 (2003). Mori, K., et al., Neurosci. Res. 43(1):69-74 (2002). Duda, D.G., et al., Br. J. Cancer 86(3):490-496 (2002). Shiratsuchi, T., et al., Biochem. Biophys. Res. Commun. 247(3):597-604 (1998). Fukushima, Y., et al., Int. J. Oncol. 13(5):967-970 (1998).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.